Prior to treatment, all diabetic groups (T2DM, T2DM+GLP-1, and T2DM+SGLT2i) showed significantly elevated blood glucose levels compared to the Control group (p < 0.001). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.